Understanding How Gut and Airway Bacteria Affect Immunotherapy Response in Lung Cancer

Researchers want to understand why some people respond better to immunotherapy for advanced lung cancer than others. This study collects airway, stool, and blood samples from patients starting PD-1 blockade treatment (either alone or with chemotherapy) to look for patterns in the bacteria living in the gut and airways, and in the immune system itself. By studying these samples over time, researchers hope to discover whether certain bacterial signatures or immune markers can predict who will benefit most from this medication.

Immunotherapy has helped many lung cancer patients, but not everyone responds equally well. Doctors don't yet have reliable ways to predict who will benefit most from the treatment. This study explores whether the bacteria naturally living in your gut and airways—which play an important role in immune function—can help explain and predict response to this medication.